Evidence map›Paper›PMID 30885698›Full record

ArticleThe Lancet. Child & adolescent health2019

Identification of new Wilms tumour predisposition genes: an exome sequencing study.

Shazia Mahamdallie, Shawn Yost, Emma Poyastro-Pearson, Esty Holt, Anna Zachariou, Sheila Seal, Anna Elliott, Matthew Clarke, Margaret Warren-Perry, Sandra Hanks and 17 more

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Child & adolescent health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Paediatric renal tumours: an update on challenges and recent developments.Virchows Archiv : an international journal of pathology · 2025
    Review
  14. Exploring theFrontiers in physiology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 4 countries.

Shazia MahamdallieDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Shawn YostDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Emma Poyastro-PearsonDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Esty HoltDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Anna ZachariouDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Sheila SealDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Anna ElliottDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Matthew ClarkeDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Margaret Warren-PerryDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Sandra HanksDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
John AndersonDepartment of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Simon BomkenThe Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Trevor ColeBirmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Roula FarahDepartment of Paediatrics, Saint George Hospital University Medical Centre, Beirut, Lebanon.
Rhoikos FurtwaenglerDepartment of Paediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Adam GlaserSchool of Medicine, University of Leeds, Leeds Institute of Data Analytics, Leeds, UK.
Richard GrundyChildren's Brain Tumour Research Centre, University of Nottingham, Queen's Medical Centre Nottingham, Nottingham, UK.
James HaydenDepartment of Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Steve LowisDepartment of Paediatric Oncology and Haematology, Bristol Royal Hospital for Children, Bristol, UK.
Frédéric MillotCIC 1402, Paediatric Oncology and Heamatology, Centre of Clinical Investigation, Poitiers, France.
James NicholsonPaediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
Milind RongheDepartment of Paediatric Oncology, Royal Hospital for Children, Queen Elizabeth University Hospital, Glasgow, UK.
Jane SkeenStarship Children's Hospital, Auckland, New Zealand.
Denise WilliamsPaediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
Daniel YeomansonDepartment of Haematology and Oncology, Sheffield Children's Hospital, Sheffield, UK.
Elise RuarkDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Nazneen RahmanDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK. Electronic address: nazneen.rahman@icr.ac.uk.
Institute of Cancer Research · GBAddenbrooke's Hospital · GBAlder Hey Children's NHS Foundation Trust · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBBristol Royal Hospital for Children · GBGreat North Children's Hospital · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBQueen Elizabeth University Hospital · GBRoyal Marsden NHS Foundation Trust · GBSaarland University · DESaint George Hospital · LBSheffield Children's Hospital · GBStarship Children's Health · NZUniversity of Leeds · GBUniversity of Nottingham · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundWilms tumour is the most common childhood renal cancer and is genetically heterogeneous. While several Wilms tumour predisposition genes have been identified, there is strong evidence that further predisposition genes are likely to exist. Our study aim was to identify new predisposition genes for Wilms tumour.

methodsIn this exome sequencing study, we analysed lymphocyte DNA from 890 individuals with Wilms tumour, including 91 affected individuals from 49 familial Wilms tumour pedigrees. We used the protein-truncating variant prioritisation method to prioritise potential disease-associated genes for further assessment. We evaluated new predisposition genes in exome sequencing data that we generated in 334 individuals with 27 other childhood cancers and in exome data from The Cancer Genome Atlas obtained from 7632 individuals with 28 adult cancers.

findingsWe identified constitutional cancer-predisposing mutations in 33 individuals with childhood cancer. The three identified genes with the strongest signal in the protein-truncating variant prioritisation analyses were TRIM28, FBXW7, and NYNRIN. 21 of 33 individuals had a mutation in TRIM28; there was a strong parent-of-origin effect, with all ten inherited mutations being maternally transmitted (p=0·00098). We also found a strong association with the rare epithelial subtype of Wilms tumour, with 14 of 16 tumours being epithelial or epithelial predominant. There were no TRIM28 mutations in individuals with other childhood or adult cancers. We identified truncating FBXW7 mutations in four individuals with Wilms tumour and a de-novo non-synonymous FBXW7 mutation in a child with a rhabdoid tumour. Biallelic truncating mutations in NYNRIN were identified in three individuals with Wilms tumour, which is highly unlikely to have occurred by chance (p<0·0001). Finally, we identified two de-novo KDM3B mutations, supporting the role of KDM3B as a childhood cancer predisposition gene.

interpretationThe four new Wilms tumour predisposition genes identified-TRIM28, FBXW7, NYNRIN, and KDM3B-are involved in diverse biological processes and, together with the other 17 known Wilms tumour predisposition genes, account for about 10% of Wilms tumour cases. The overlap between these 21 constitutionally mutated predisposition genes and 20 genes somatically mutated in Wilms tumour is limited, consisting of only four genes. We recommend that all individuals with Wilms tumour should be offered genetic testing and particularly, those with epithelial Wilms tumour should be offered TRIM28 genetic testing. Only a third of the familial Wilms tumour clusters we analysed were attributable to known genes, indicating that further Wilms tumour predisposition factors await discovery.

fundingWellcome Trust.

Indexed as

Genes, Wilms TumorAdolescentAdultChildChild, PreschoolExome SequencingF-Box-WD Repeat-Containing Protein 7FemaleGenetic MarkersGenetic Predisposition to DiseaseHumansJumonji Domain-Containing Histone DemethylasesMaleMiddle AgedMutationPrognosisF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanGenetic MarkersJumonji Domain-Containing Histone DemethylasesKDM3B protein, humanTRIM28 protein, humanTripartite Motif-Containing Protein 28

Identifiers

PMID30885698
PMCPMC6472290
OpenAlexW2921680432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.